MedImmune Inc. is a wholly owned subsidiary of AstraZeneca PLC, a pharmaceutical company headquartered in London. MedImmune is best known for its nasal flu vaccine, FluMist. Between 10 million and 12 million doses of the vaccine were sold in the United States last year. In addition, the biotechnology company developed and sells Synagis, which protects high-risk infants’ lungs from severe respiratory infections. FluMist and Synagis together accounted for more than $1.3 billion of AstraZeneca’s 2008 sales of $31.6 billion.
MedImmune has about 3,500 employees globally; 1,500 of them work at the company’s headquarters in Gaithersburg, Md. The company has three facilities in California, two in Pennsylvania and sites in Kentucky, the Netherlands and Liverpool, England, plus a research and development arm in Cambridge, England. AstraZeneca has more than 65,000 employees worldwide.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
